Patients set to benefit from five-minute breast cancer treatment
An injection that cuts the amount of time breast cancer patients spend in hospital from two and a half hours to as little as five minutes is being rolled out across the country by NHS England.
Breast cancer patients undergoing chemotherapy will be offered a new combined treatment called PHESGO, which is injected and takes as little as five minutes to prepare and administer, compared with two infusions that can take up to two and a half hours.
More than 3,600 new patients each year will benefit from the treatment, as well as others who will switch from the treatment they are on to the single injection, following an NHS deal with the manufacturer.
The injection will be offered to eligible people with HER2-positive breast cancer, which accounts for 15% of all breast cancers, and can be given alongside chemotherapy or on its own.
The five-minute jab significantly cuts the COVID infection risk for cancer patients by reducing the amount of time spent in hospital and frees up time for clinicians in chemotherapy units.
The announcement is the latest in a series of innovations in cancer care during the pandemic, including COVID-secure surgery hubs that were set up across the country and £160 million invested by NHS England in ‘covid-friendly’ cancer drugs, that treat patients without having such a big impact on their immune system or offer other benefits such as fewer hospital visits.
Since the start of the pandemic, 228,000 people have started NHS treatment for cancer, 95% of whom did so within a month. Hospitals across England have also carried out more than two cancer procedures for every patient they treated for coronavirus last year.
NHS national clinical director for cancer, Peter Johnson, said: “The NHS has continued to adopt new treatments rapidly throughout the pandemic, to improve cancer care for patients. This new injection, which can substantially cut treatment time for people with breast cancer, is the latest in a series of changes which have meant the NHS has been able to deliver vital cancer treatment while keeping patients safe from COVID.
“I am delighted that this is now available to people having breast cancer treatment, limiting the time they need to spend in hospital and giving the NHS another way to continue treating as many cancer patients as possible, as we have done throughout the pandemic.”
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said: “Approval of Phesgo being used on the NHS in England is fantastic news as thousands of women with HER2 positive breast cancer will now benefit from a quicker and kinder treatment method.
“Reducing the time patients need to spend in hospital, this more efficient treatment method also promises to free up precious time for healthcare professionals when the NHS is already under unprecedented strain due to COVID-19.
“The announcement reflects the latest of continued advances in breast cancer treatment, and now we hope to see Roche and NHS decision-makers working together to ensure Phesgo is rapidly made available across all of the UK so that even more patients and healthcare professionals alike can reap its benefits.”